Patents by Inventor Wenci Gong

Wenci Gong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250154277
    Abstract: This disclosure provides anti-5T4 antibodies, variants thereof and humanized versions. The newly disclosed antibodies exhibited high affinity to the 5T4 protein and can be used to treat cancers.
    Type: Application
    Filed: February 21, 2023
    Publication date: May 15, 2025
    Inventors: Fang LIU, Wenci GONG, Zhijian CAI, Liu YANG, Shan GAO, Wenqing JIANG, Lei FANG
  • Publication number: 20240417482
    Abstract: Provided are single domain anti-4-1BB antibodies and polypeptides, such as bispecific antibodies and chimeric antigen receptors, that include these single domain antibodies. Methods of using the antibodies or polypeptides for treating and diagnosing diseases such as cancer are also provided.
    Type: Application
    Filed: October 12, 2022
    Publication date: December 19, 2024
    Inventors: Wenci GONG, Liu YANG, Shan GAO, Yuanyuan YANG, Lei FANG
  • Publication number: 20240417469
    Abstract: Antibodies against the CD3 complex are being tested in bispecific and trispecific antibody formats that further recognize a tumor-associated antigen. Such antibodies are commonly associated with on-target toxicities, however. It is discovered herein that the toxicities can be reduced or avoided if the bispecific and trispecific antibody adopts a suitable structure and uses an anti-CD3 unit having a suitably balanced T cell activation activity level. Provided are such bispecific and trispecific antibody structures. Also provided is a broad spectrum of anti-CD3 antibodies having different levels of T cell activation activities that can be readily used in different scenarios.
    Type: Application
    Filed: October 12, 2022
    Publication date: December 19, 2024
    Inventors: Lei FANG, Liu YANG, Shan GAO, Wenci GONG, Yuanyuan YANG
  • Publication number: 20240287208
    Abstract: Provided are CD40 agonist antibodies which have greatly higher CD40 activation activity in the presence of concurrent tumor-associated antigen (TAA) binding than without such concurrent binding. Such TAA-dependent CD40 agonism results in greatly improved therapeutic index, reducing or totally eliminating adverse events commonly associated with CD40 activation, such as cytokine release syndrome or liver toxicity. Also provided are bi- and multi-specific antibodies and polypeptides, such as chimeric antigen receptors, that incorporate these antibodies, optionally with an anti-TAA unit. Methods of using the antibodies or polypeptides for treating and diagnosing diseases such as cancer are also provided.
    Type: Application
    Filed: February 20, 2024
    Publication date: August 29, 2024
    Inventors: Fang LIU, Yuanyuan YANG, Wenci GONG, Zhijian CAI, Wenqing JIANG, Lei FANG
  • Publication number: 20240247073
    Abstract: Provided are CD40 agonist antibodies which have greatly higher CD40 activation activity in the presence of concurrent tumor-associated antigen (TAA) binding than without such concurrent binding. Such TAA-dependent CD40 agonism results in greatly improved therapeutic index, reducing or totally eliminating adverse events commonly associated with CD40 activation, such as cytokine release syndrome or liver toxicity. Also provided are bi- and multi-specific antibodies and polypeptides, such as chimeric antigen receptors, that incorporate these antibodies, optionally with an anti-TAA unit. Methods of using the antibodies or polypeptides for treating and diagnosing diseases such as cancer are also provided.
    Type: Application
    Filed: February 20, 2024
    Publication date: July 25, 2024
    Inventors: Fang LIU, Yuanyuan YANG, Wenci GONG, Zhijian CAI, Wenqing JIANG, Lei FANG
  • Publication number: 20240209109
    Abstract: Provided are CD40 agonist antibodies which have greatly higher CD40 activation activity in the presence of concurrent tumor-associated antigen (TAA) binding than without such concurrent binding. Such TAA-dependent CD40 agonism results in greatly improved therapeutic index, reducing or totally eliminating adverse events commonly associated with CD40 activation, such as cytokine release syndrome or liver toxicity. Also provided are bi- and multi-specific antibodies and polypeptides, such as chimeric antigen receptors, that incorporate these antibodies, optionally with an anti-TAA unit. Methods of using the antibodies or polypeptides for treating and diagnosing diseases such as cancer are also provided.
    Type: Application
    Filed: February 20, 2024
    Publication date: June 27, 2024
    Inventors: Fang LIU, Yuanyuan YANG, Wenci GONG, Zhijian CAI, Wenqing JIANG, Lei FANG
  • Publication number: 20240066121
    Abstract: Provided are anti-CD47 antibodies and fragments thereof. The antibodies and fragments thereof specifically bind to the CD47 protein. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and atherosclerosis are also provided.
    Type: Application
    Filed: August 22, 2023
    Publication date: February 29, 2024
    Inventors: Wenci Gong, Yiwei Tou
  • Patent number: 11883495
    Abstract: Provided are anti-CD47 antibodies and fragments thereof. The antibodies and fragments thereof specifically bind to the CD47 protein. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and atherosclerosis are also provided.
    Type: Grant
    Filed: May 10, 2021
    Date of Patent: January 30, 2024
    Assignee: Lepu Biopharma Co., Ltd.
    Inventors: Wenci Gong, Yiwei Tou
  • Publication number: 20230287125
    Abstract: Provided are anti-PD-L1 antibodies with superior activities in blocking the PD-1 and PD-L1 interactions. Also provided are multifunctional molecules that include the anti-PD-L1 antibodies or fragments thereof fused to an extracellular domain of human TGF-beta receptor type-2.
    Type: Application
    Filed: July 27, 2021
    Publication date: September 14, 2023
    Inventors: Wenci GONG, Yiwei TOU
  • Publication number: 20220127357
    Abstract: Provided are anti-CD47 antibodies and fragments thereof. The antibodies and fragments thereof specifically bind to the CD47 protein. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and atherosclerosis are also provided.
    Type: Application
    Filed: May 10, 2021
    Publication date: April 28, 2022
    Inventors: Wenci Gong, Yiwei Tou
  • Patent number: 11028174
    Abstract: Provided are anti-PD-L1 antibodies with superior activities in blocking the PD-1 and PD-L1 interactions. Also provided are multifunctional molecules that include the anti-PD-L1 antibodies or fragments thereof fused to an extracellular domain of human TGF-beta receptor type-2.
    Type: Grant
    Filed: August 28, 2020
    Date of Patent: June 8, 2021
    Assignee: Lepu Biopharma Co., Ltd.
    Inventors: Wenci Gong, Yiwei Tou
  • Patent number: 11028172
    Abstract: Provided are anti-TIGIT antibodies and fragments thereof. The antibodies and fragments thereof specifically bind to the TIGIT protein. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and viral infections are also provided.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: June 8, 2021
    Assignee: Lepu Biopharma Co., Ltd.
    Inventors: Wenci Gong, Yiwei Tou
  • Patent number: 11014984
    Abstract: Provided are anti-CD47 antibodies and fragments thereof. The antibodies and fragments thereof specifically bind to the CD47 protein. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and atherosclerosis are also provided.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: May 25, 2021
    Assignee: Lepu Biopharma Co., Ltd.
    Inventors: Wenci Gong, Yiwei Tou
  • Publication number: 20200399367
    Abstract: Provided are anti-CD47 antibodies and fragments thereof. The antibodies and fragments thereof specifically bind to the CD47 protein. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and atherosclerosis are also provided.
    Type: Application
    Filed: August 21, 2020
    Publication date: December 24, 2020
    Inventors: Wenci Gong, Zhaokun Meng, Yiwei Tou